Genprex

Tagged: Fast Track Designation

Genprex Wins FDA Fast Track Status for its Oncoprex Therapy in Combination with AstraZeneca’s Tagrisso

Genprex Inc (NASDAQ:GNPX) announced that the US Food and Drug Administration has granted Fast Track Designation for its Oncoprex immunogene therapy to treat lung cancer.

Read More

Genprex Receives U.S. FDA Fast Track Designation for Gene Therapy that Targets Lung Cancer

Genprex announced that the FDA has granted Fast Track Designation for Genprex’s Oncoprex™ immunogene therapy in combination with EGFR inhibitor osimertinib for the treatment of non-small cell lung cancer (NSCLC) patients with EFGR mutations that progressed after treatment with osimertinib alone.

Read More